Biodesix Inc (OQ:BDSX)

Business Focus: Medical & Diagnostic Laboratories

Sector:  Healthcare Industry:  Healthcare Facilities & Services
 
See Regulatory Filings on SEC
Company Contact
Address: Suite 100, 2970 Wilderness Place
BOULDER CO 80301
Tel: 1-212-9152568
Website: https://www.biodesix.com
IR: See website
<
Key People
Scott Hutton
President, Chief Executive Officer, Director
Robin Harper Cowie
Chief Financial Officer, Treasurer, Secretary
Christopher Vazquez
Chief Accounting Officer
Business Overview
Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
Financial Overview
For the fiscal year ended 31 December 2023, Biodesix Inc revenues increased 28% to $49.1M. Net loss decreased 20% to $52.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects (Loss) gain on debt extinguishments, net decrease from $7M (expense) to $0K, Research and development - Balancing v decrease of 24% to $9.7M (expense).
Employees: 217 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $155.57M as of Dec 31, 2023
Annual revenue (TTM): $49.09M as of Dec 31, 2023
EBITDA (TTM): -$37.97M as of Dec 31, 2023
Net annual income (TTM): -$52.15M as of Dec 31, 2023
Free cash flow (TTM): -$45.93M as of Dec 31, 2023
Net Debt Last Fiscal Year: $8.99M as of Dec 31, 2023
Shares outstanding: 113,627,715 as of Apr 5, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.